MedTrace Logo

Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients

NCT02325856 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2016-02-02

Study results available
· View outcomes & findings →

Summary

A reasonable and simple algorithm was used to guide the dry weight determination with Body Composition Monitor with the principle of Bioimpedance Spectroscopy (BCM-BIS) and analyze the feasibility of this algorithm and evaluate the influence of BCM-BIS-guided fluid management on the incidence of dialysis morbidities and clinical outcomes in maintenance hemodialysis (MHD) patients.

Conditions

  • Fluid Overload

Interventions

DEVICE

Bioimpedance Spectroscopy

Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.

BEHAVIORAL

Clinical judgement

Sponsors & Collaborators

  • Nephrocare AsiaPacific

    collaborator UNKNOWN

  • An Hsin QingShui Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02325856 on ClinicalTrials.gov